Ghassan Abou Alfa
Contributor at Freelance
@MSKCancerCenter Medical Oncologist, liver, cholangiocarcinoma, gallbladder, biliary cancer specialist. Global healthcare specialist. Patients’ advocate.
Articles
-
Jan 11, 2024 |
jamanetwork.com | Ghassan Abou Alfa |Bruno Sangro |Sarah Cappuyns
HIMALAYA Overall Survival Prominence and Other Routes to the Peak Critical Appraisal of Recommendations on Systemic Therapies for Advanced HCC Sarah Cappuyns, MD; Virginia Corbett, MD; Mark Yarchoan, MD; Richard S. Finn, MD; Josep M. Llovet, MD, PhD HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply Josep M. Llovet, MD, PhD; Sarah Cappuyns, MD, PhD; Richard S.
-
Sep 6, 2023 |
futuremedicine.com | Ghassan Abou Alfa |George Lau |Masatoshi Kudo |Stephen Chan
This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereFinancial & competing interests disclosureThis study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee.
-
Aug 3, 2023 |
onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa
Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.
-
Aug 3, 2023 |
onclive.com | Rachna T Shroff |Manish Shah |Julio Gutiérrez |Ghassan Abou Alfa
Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.
-
Jul 28, 2023 |
targetedonc.com | Ghassan Abou Alfa
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the phase 3 RATIONALE-301 trial (NCT03412773) which evaluated frontline tislelizumab vs sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC). In the RATIONALE-301 trial, tislelizumab demonstrated improved health-related quality of life, physical functioning, fatigue, and HCC symptom index when compared with sorafenib. However, the agent did not reduce pain significantly vs sorafenib.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 5K
- Tweets
- 2K
- DMs Open
- No
Congratulations and thank you @ASCO for a superb International Clinical Research Scholars Program in #Addisababa #Ethiopia. It is a honor and delight to celebrate #Africa ‘s new generation of scholars unlimited enthusiasm and focused care! https://t.co/DaTqqlw3dZ
Congratulations and thank you @Layalmahmasani on bolf needed effort of an International Fibrolamellar Cancer Registry of @MSKCancerCenter @MSK_DeptOfMed Opportunities and Challenges | JCO Global Oncology https://t.co/V3CSNBTBEY
Thks @hkumed Thomas Yau Jeffrey Wong for contribution @MSKCancerCenter @MSK_DeptOfMed @MSKCME quarterly East West Liver + @wei_ac @MichaelDAngeli2. Thanks @FudanUni Zhongshan Hopsital Jian Zhou and team, @nccsingapore Jocelynne Lee @AsanMedicalCtr @changhoon_yoo https://t.co/w729wOnB1c
